Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions
With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management.
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.
Shares of diagnostic company Exact Sciences Corporation (NASDAQEXAS)
fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened significantly while revenue trudged along. While EXAS deserves some credit for the modest top-line beat, the company remained unprofitable on a GAAP basis, and this is also wiping out its cash flow headroom as free cash flow margin also fell significantly during the quarter.
On the other hand, Exact Sciences blew past analysts' constant currency revenue expectations this quarter, and its adjusted EPS and EBITDA outperformed. Still, we think this was still a mixed yet challenging quarter.
Diagnostic company Exact Sciences Corporation (NASDAQEXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 billion, close to analysts’ estimates. Its non-GAAP loss of $0.06 per share was 67.9% above analysts’ consensus estimates.
Exact Sciences Corp (NASDAQEXAS) reported fourth-quarter financial results after the market close on Wednesday. Here's a look at the key details from the quarter.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $713 million for the fourth quarter of 2024 and $2.76 billion for the full year of 2024, both ended December 31, 2024.
All three major U.S. indices are red in Wednesday's midday trading as investors weighed President Donald Trump's proposed tariffs on auto imports, pharmaceuticals and semiconductors.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) meeting January 23-25, 2025, in San Francisco.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI.) Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively1. The complete findings of the study, which primarily included patients with stage III colon cancer, will be published in a peer-reviewed scientific journal on January 25.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024.
